Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?

Other than patients with the KRAS mutation who demonstrate relatively favorable response to ICB, a single-agent ICB therapy should be considered for those who retain good performance status but have no other therapeutic options available. Further studies on the combination of ICB and TKI are needed to identify the most viable pair regarding safety. Additional studies using novel combination partners, such as anti-VEGF inhibitors, are also warranted.
Lee & Ahn 2020 Current Opinion in Oncology. 33(1):64-72…